Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 1, 2015, Pages 18-27

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; Gastric cancer; Ramucirumab; VEGF

Indexed keywords

AFATINIB; AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOVITINIB; EPIGALLOCATECHIN GALLATE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LENTIVIRUS VECTOR; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM COMPLEX; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANEMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; DECREASED APPETITE; DIARRHEA; FATIGUE; GENE EXPRESSION; GENE SILENCING; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; RNA INTERFERENCE; SOLID TUMOR; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH PERFORATION; STOMATITIS; THROMBOEMBOLISM; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; ANIMAL; METABOLISM; PROCEDURES; STOMACH NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916199585     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.012     Document Type: Review

References (52)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. American Cancer Society Cancer facts and figures 2011 2011, American Cancer Society, Atlanta, GA.
4. Forman D., Burley V. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006, 20:633-649.
5. Fitzgerald R., Hardwick R., Huntsman D. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
6. Kordes S., Cats A., Meijer S.L., van Laarhoven H.W. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol 2014, 90(April (1)):68-76. [Epub 12.10.13]. 10.1016/j.critrevonc.2013.10.004.
7. Kasper S., Schuler M. Targeted therapies in gastroesophageal cancer. Eur J Cancer 2014, (February). pii:S0959-8049(14)00043-4. 10.1016/j.ejca.2014.01.009.
8. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
9. Tischer E., Gospodarowicz D., Mitchell R., et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989, 165:1198-1206.
10. Koch S., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012, 2(a006502).
11. Chung A.S., Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011, 27:563-584.
12. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006, 12:5018-5022.
13. Hamerlik P., Lathia J.D., Rasmussen R., et al. Autocrine VEGF-VEGFR2-neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 2012, 209:507-520.
14. Prud'homme G.J., Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012, 3:921-939.
15. Parker M.W., Guo H.F., Li X., Linkugel A.D., Vander Kooi C.W. Function of members of the neuropilin family as essential pleiotropic cell surface receptors. Biochemistry 2012, 51:9437-9446.
16. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat Rev Cancer 2013, 13(December (12)):871-882. 10.1038/nrc3627.
17. Dong F., Ha X.Q. Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy. Chin Med J (Engl) 2010, 123(17):2454-2460.
18. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146(6):873-887.
19. Grunewald M., Avraham I., Dor Y., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124(1):175-189.
20. Melero-Martin J.M., Dudley A.C. Concise review: vascular stem cells and tumor angiogenesis. Stem Cells 2011, 29(2):163-168.
21. De Mello R.A., Costa B.M., Reis R.M., Hespanhol V. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov 2012, 7(1):118-131.
22. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10(7):505-514.
23. Lichtenberger B.M., Tan P.K., Niederleithner H., et al. Autocrine BVEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 2010, 140(2):268-279.
24. Alevizakos M., Kaltsas S., Syrigos K.N. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol 2013, 72(December (6)):1169-1181. [Epub 02.10.13]. 10.1007/s00280-013-2298-3.
25. Liu L., Ma X.L., Xiao Z.L., Li M., Cheng S.H., Wei Y.Q. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev 2012, 13(7):3089-3097.
26. Scartozzi M., Giampieri R., Loretelli C., et al. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics 2013, 14(December (16)):1991-1998. [Epub 03.10.13]. 10.2217/pgs.13.185.
27. Shah M.A., Khanin R., Tang L., et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011, 17(May (9)):2693-2701. [Epub 23.03.11]. 10.1158/1078-0432.CCR-10-2203.
28. Shah M., Cutsem E., Kang Y., et al. J Clin Oncol (Meeting Abstracts) February 2012, 30(4 suppl. 5).
29. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29(October (30)):3968-3976. [Epub 15.08.11]. 10.1200/JCO.2011.36.2236.
30. Shah M.A., Jhawer M., Ilson D.H., et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29(March (7)):868-874. [Epub 28.12.10]. 10.1200/JCO.2010.32.0770.
31. Shen L., Li J., Xu J., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2014, (February). [Epub ahead of print].
32. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24(November (33)):5201-5206.
33. El-Rayes B.F., Zalupski M., Bekai-Saab T., et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010, 21(October (10)):1999-2004. [Epub 23.03.10]. 10.1093/annonc/mdq065.
34. Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383(January (9911)):31-39. [Epub 03.10.13]. 10.1016/S0140-6736(13)61719-5.
35. Wilke H., Van Cutsem E., Oh S., et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel vs. placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP 12-0922 (I4T-IE-JVBE). J Clin Oncol 2014, 32(Suppl. 3). [abstr LBA7].
36. Yi J.H., Lee J., Lee J., et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012, 106(April (9)):1469-1474. [Epub 29.03.12]. 10.1038/bjc.2012.100.
37. Moehler M., Mueller A., Hartmann J.T., et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011, 47(July (10)):1511-1520. [Epub 09.05.11]. 10.1016/j.ejca.2011.04.006.
38. Bang Y.J., Kang Y.K., Kang W.K., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011, 29(December (6)):1449-1458. [Epub 12.05.10]. 10.1007/s10637-010-9438-y.
39. Sun W., Powell M., O'Dwyer P.J., Catalano P., Ansari R.H., Benson A.B. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010, 28(June (18)):2947-2951. [Epub 10.05.10]. 10.1200/JCO.2009.27.7988.
40. Satoh T., Yamada Y., Muro K., et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012, 69(February (2)):439-446. [Epub 19.08.11]. 10.1007/s00280-011-1723-8.
41. Li J., Qin S., Xu J., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013, 31(September (26)):3219-3225. [Epub 05.08.13]. 10.1200/JCO.2013.48.8585.
42. Wu H., Xin Y., Xiao Y., Zhao J. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother Radiopharm 2012, 27(April (3)):204-209. [Epub 27.01.12]. 10.1089/cbr.2011.1103.
43. Wu H., Xin Y., Zhao J., et al. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol 2011, 68(October (4)):879-887. [Epub 03.02.11]. 10.1007/s00280-011-1563-6.
44. Cejka D., Preusser M., Woehrer A., et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008, 7(September (9)):1377-1385. [Epub 02.09.08].
45. He S., Shen J., Hong L., Niu L., Niu D. Capecitabine metronomic chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol 2012, 29(March (1)):100-106. [Epub 25.01.11]. 10.1007/s12032-010-9791-x.
46. Wang X., Chen X., Fang J., Yang C. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol 2013, 6(4):586-597. [Epub 15.03.13].
47. Yao J., Da M., Guo T., Duan Y., Zhang Y. RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice. Tumour Biol 2013, 34(June (3)):1493-1501. [Epub 10.03.13]. 10.1007/s13277-013-0674-6.
48. Hwang J.E., Lee J.H., Park M.R., et al. Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Yonsei Med J 2013, 54(March (2)):374-380. 10.3349/ymj.2013.54.2.374.
49. Wu H., Xin Y., Xu C., Xiao Y. Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp Ther Med 2012, 3(April (4)):650-654. [Epub 10.01.12].
50. Wu H., Xin Y., Xiao Y., Zhao J. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother Radiopharm 2012, 27(April (3)):204-209. [Epub 27.01.12]. 10.1089/cbr.2011.1103.
51. Singh R., Kim W.J., Kim P.H., Hong H.J. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med 2013, 45(November):e52. 10.1038/emm.2013.111.
52. Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61(May (5)):673-684. [Epub 07.02.12]. 10.1136/gutjnl-2011-301839.